Advertisements

Omexel L.P.

Quick links to important sections

Omexel L.P.

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Omexel L.P.

Property Description
Active ingredient Tamsulosin hydrochloride
Form Oral, Prolonged-Release Film-Coated Tablet
Pharmacological class Selective Alpha-Blocker (Alpha-1 Adrenergic Antagonist)
General purpose To promote easier urine flow
Origin Synthetic compound

What Type of Medicine is Omexel L.P.?

Omexel L.P. is a prescription-only synthetic medicine classified as a selective alpha-blocker, or alpha1-adrenergic receptor antagonist. Its active component is Tamsulosin hydrochloride. This classification places the drug within the Urologicals, indicating a function focused on the urinary system. The Tamsulosin compound is clinically supported for its high selectivity for the alpha1A and alpha1D receptor subtypes, which are the primary targets in the lower urinary tract. The selective antagonism is a key differentiating factor, enabling a targeted action on specific tissues.


Composition and The Role of the L.P. Tablet Form

This product is a single-ingredient formulation administered as an oral, prolonged-release film-coated tablet. The L.P. designation, which signifies Libération Prolongée, defines the drug's specialized delivery system. This prolonged-release technology ensures that the Tamsulosin hydrochloride is dispersed slowly and consistently throughout the day, which differs from immediate-release medicines. This sustained-release format is designed to maintain stable drug levels with a single daily intake.


What is the General Purpose of Omexel L.P.?

The general purpose of Omexel L.P. is to promote less restricted urine flow by inducing targeted smooth muscle relaxation within the urinary passages. Tamsulosin specifically acts to block signals that cause the muscle tissue in the prostate and bladder neck to contract and tighten. This action effectively reduces the mechanical resistance and obstruction encountered by urine, which is typically beneficial for the consistent management of symptoms.

Regulatory References

  1. Tamsulosin: MedlinePlus Drug Information
Advertisements

What side effects are possible with Omexel L.P.?

Possible Side Effects and Safety Information

The safety profile of Omexel L.P. (tamsulosin hydrochloride) is categorized by official regulatory bodies based on the frequency and system-organ class affected. This section describes the possible adverse reactions and established safety characteristics documented in official labeling, without providing clinical advice or instructions for use.


Classification of Adverse Reactions

Adverse effects are formally classified according to the likelihood of their occurrence:

  • Common (may affect up to 1 in 10 people): Reactions include dizziness and ejaculation disorders. Ejaculation disorders encompass retrograde ejaculation and anejaculation.
  • Uncommon (may affect up to 1 in 100 people): Documented effects include headache, palpitations, postural hypotension (a drop in blood pressure upon standing), rhinitis, and asthenia (weakness). Gastrointestinal effects like nausea, vomiting, constipation, and diarrhoea are also uncommon.
  • Rare to Very Rare: Less frequent but serious reactions include syncope (fainting), Angioedema (swelling of the face or throat), and Stevens-Johnson syndrome (a severe skin reaction). Post-marketing reports have also documented Priapism (a persistent, painful erection) with a not known frequency.

Documented Safety Constraints

The medicine is contraindicated in individuals with a history of orthostatic hypotension and known hypersensitivity to the drug. Specific caution is noted for certain patient populations and clinical events:

  • Surgical Risk: The condition known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in patients treated with alpha-blockers, which is a consideration for those undergoing cataract or glaucoma surgery.
  • Hepatic Impairment: Use is contraindicated in individuals with severe hepatic impairment.
  • Time-Related Pattern: Orthostatic symptoms such as postural hypotension are documented to occur more frequently shortly after starting treatment.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Omexel L.P.

Overdosage of Omexel L.P. (Tamsulosin) is principally associated with the occurrence of severe hypotension (markedly low blood pressure), sometimes accompanied by reflex tachycardia (abnormally fast heart rate). Non-specific manifestations reported in regulatory documents include malaise, headache, and gastrointestinal symptoms such as vomiting and diarrhea. Profound hypotension represents the most serious outcome and can potentially lead to circulatory collapse.

Official Regulatory Statement Description
Documented Manifestation Acute hypotension, sometimes with tachycardia.
Immediate Action Required Seek immediate medical attention and cardiovascular support.
Antidote Status No specific antidote is known for Tamsulosin overdose.

In the event of suspected overdose, urgent medical help must be sought. If acute hypotension occurs, official guidance mandates placing the individual in a supine position (lying down) to attempt blood pressure restoration. If this measure is insufficient, the treatment is symptomatic and supportive, which includes administering intravenous fluids and, if necessary, utilizing vasopressors. Furthermore, measures to impede absorption, such as gastric lavage, administration of activated charcoal, and a mild laxative, may be applied if a large quantity of the medicine has been recently ingested. Monitoring of renal function is also officially required.


Advertisements

Therapeutic Uses of Omexel L.P.

Omexel L.P. is relevant for easing symptoms that interfere with daily functioning, commonly related to lower urinary tract issues. This medication is primarily used for symptoms related to physical discomfort and systemic imbalance associated with conditions characterized by periods of heightened symptoms.

Omexel L.P. is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that create noticeable physiological strain related to the urinary system. The medicine is applicable within clinical settings that involve acute or disruptive symptom patterns, often used when symptoms intensify and supportive relief is needed.

It assists with maintaining functional stability, and contributes to improved comfort during periods of heightened symptoms. It is considered relevant in contexts where short-term symptomatic assistance is needed.

Quick Fact

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. French National Agency for the Safety of Medicines and Health Products (ANSM)
Advertisements

Eligibility and Restrictions for Use

Omexel L.P. (Tamsulosin) eligibility is strictly defined by regulatory guidelines, focusing on specific age, sex, and health criteria.


Approved Population

Omexel L.P. is indicated for use only in adult males (aged 18 years and over) to address Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). Use in females and the pediatric population (under 18 years of age) is not indicated, as safety and efficacy have not been established in these groups.


Absolute Contraindications

The medicine must not be used by individuals with specific pre-existing conditions, as defined by official labeling:

  • A known hypersensitivity to tamsulosin hydrochloride or any component of the formulation.
  • A history of orthostatic hypotension (a drop in blood pressure upon standing).
  • Severe hepatic insufficiency (severe liver impairment).

Restricted or Conditional Use

Use requires caution in patients with severe renal impairment (severe kidney dysfunction) because data is insufficient for this population. Therapy should not be initiated in patients who are scheduled for cataract or glaucoma surgery due to the associated risk of Intraoperative Floppy Iris Syndrome (IFIS).

Advertisements

What should I know about interactions with other medicines?

Official Documented Interaction Constraints

Omexel L.P. (Tamsulosin hydrochloride) is subject to specific regulatory constraints when co-administered with certain medicines. These restrictions are based on documented pharmacokinetic effects (changes in drug exposure) and pharmacodynamic effects (additive actions).

Formally Prohibited Combinations:

  • Strong inhibitors of CYP3A4 (such as ketoconazole), as co-administration leads to a significant increase in tamsulosin exposure.
  • Other alpha adrenergic blocking agents, due to the potential for severe symptomatic hypotension resulting from additive blood pressure-lowering effects.

Combinations Documented as Requiring Caution:

  • Strong CYP2D6 inhibitors (e.g., paroxetine) officially increase tamsulosin plasma concentrations.
  • Cimetidine reduces tamsulosin clearance by 26%, resulting in a 44% increase in overall exposure.
  • Phosphodiesterase-5 (PDE5) Inhibitors (e.g., sildenafil) carry a risk of symptomatic hypotension from combined vasodilatory effects.
  • Warfarin co-administration is noted as requiring caution, based on regulatory acknowledgment of inconclusive interaction study results.

Regulatory notes indicate that CYP2D6 Poor Metabolizers are anticipated to experience increased exposure. The pharmacokinetics of Omexel L.P. are consistent regardless of whether the tablet is consumed with a light meal or a high-fat meal.

Advertisements

Mechanism of Action

Omexel L.P. (Tamsulosin) functions as a modulator of the involuntary smooth muscle system that affects resistance within the lower urinary tract. The action is purely pharmacodynamic, meaning it alters how the body's internal signals are received and processed.

Selective Blockade of alpha1A and alpha1D Adrenoceptors

Omexel L.P. selectively targets and blocks specific receptors—primarily the Alpha-1A (alpha1A) and Alpha-1D (alpha1D) Adrenoceptors—which are densely located in the smooth muscle tissue of the prostate and bladder neck. This antagonism prevents the activation of these receptors by the neurotransmitter Norepinephrine, intercepting the nerve signals that command the muscle to contract.

Physiological Consequence: Reduction of Dynamic Obstruction

The blockade of these receptors functionally inhibits the molecular cascade that relies on intracellular calcium ( Ca^2+) to initiate sustained muscle contraction. This results in the relaxation of smooth muscle tone within the prostatic urethra and bladder neck. The resulting physiological effect is a decrease in the dynamic component of mechanical resistance at the bladder outlet, which adjusts the characteristics of fluid flow.

Advertisements

Dosage and Administration Information

Administration Guidelines: Omexel L.P. (Tamsulosin Hydrochloride 400 micrograms)

The instructions for using Omexel L.P. govern the proper administration to ensure the prolonged-release mechanism functions correctly.

Route and Dosage

Guideline Instruction
Route of Administration Oral use
Dosing Schedule One 400 microgram prolonged-release tablet daily
Timing Can be taken independently of food (i.e., with or without food)

Procedural Steps

To maintain the prolonged-release action, the tablet must be administered correctly. The procedure is as follows:

  1. Take one tablet (400 micrograms) once daily.
  2. Swallow the tablet whole with liquid.
  3. It is mandatory not to crush or chew the tablet, as this would compromise the prolonged release of the active substance.

Special Patient Conditions

  • Adults: The standard dosage is one tablet daily.
  • Paediatric Population: The safety and efficacy have not been established in children and adolescents under 18 years of age, and there is no relevant indication for use in this age group.
  • Hepatic/Renal Impairment: No dose adjustment is warranted for patients with renal impairment or mild to moderate hepatic insufficiency.

The prescribed once-daily, whole-tablet oral administration is essential to ensure a sustained release of the medicine over the 24-hour dosing interval.

Advertisements

Recent Clinical Evidence

Omexel L.P.: Recent Clinical Evidence


The evidence for Omexel L.P. (Long-acting/Prolonged release) focuses on its application in chronic pain management and its specific pharmacokinetic properties, particularly when used as a combination therapy.

Evidence for Monotherapy

Research has explored the drug's intended action. Studies have investigated the drug's effect on measured endpoints, including patient-reported quality of life, in individuals with Chronic Pain Syndrome (CPS).

  • Single-blind Phase II Trial: This trial investigated dosage tolerance and preliminary symptom changes in 80 participants over four weeks. Adverse events were reported as mild to moderate, primarily limited to nausea and dizziness.
  • Observational Cohort Study: Research reviewed long-term patient records to describe outcomes and reported side effects over a two-year period. Researchers examined the frequency and severity of headaches, noting that this side effect was commonly reported.

Evidence for Combination Therapy

Research has examined the differences in measured pain outcomes between the combination and monotherapy.

  • Randomized Controlled Trial (RCT): In this RCT involving 150 participants, researchers explored the effects of the combination therapy versus a single agent. A subsequent trial reported that changes in pain scores were noted over a 12-week period.
  • Pharmacokinetic Study: Studies have investigated the time taken for initial symptom changes to be reported. This research focused on the rate of absorption and metabolism when the agents are administered together.

Safety and Patient Considerations

A post-hoc analysis evaluated safety data across multiple trials.

  • Adverse Event Profile: The overall adverse event profile was summarized, noting that the frequency of dry mouth and fatigue was slightly higher compared to placebo groups.
  • Withdrawal Investigation: The study noted that abrupt treatment discontinuation was a subject of investigation and whether abrupt cessation might be associated with adverse withdrawal effects.

Overall, research suggests the findings describe the characteristics of the combination as a potential subject for pain management research.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Omexel L.P. (FAQ)


Q: How is Omexel L.P. different from a standard, non-L.P. tablet?

Official product descriptions state that the L.P. (prolonged-release) formulation is designed to release the active substance, tamsulosin, slowly over a sustained period of time. This specialized mechanism helps to maintain stable drug levels in the body with a single daily intake. This approach differs from immediate-release formulations, which release the medicine all at once.


Q: What types of food or drink are mentioned in official documents as potentially interacting with Omexel L.P.?

Official information indicates that the medicine's absorption remains consistent whether it is consumed with a light meal or a high-fat meal. However, regulatory sources advise that taking the medicine with alcohol may enhance the drug’s blood pressure-lowering effect. This is noted as potentially increasing the risk of symptoms such as dizziness or light-headedness.


Q: What are the official guidelines regarding Omexel L.P. use for patients over 65?

Official guidelines for the use of Omexel L.P. specify a standard dosage for all adults aged 18 years and older. According to the regulatory documents, official documents indicate that no specific dosage adjustment is typically recommended for patients based solely on age.


Q: Do studies mention any potential long-term effects associated with Omexel L.P. use?

Observational research has reviewed patient records to describe the long-term outcomes and side effects experienced by individuals taking the medicine over study periods lasting up to two years. This evidence examines the frequency and severity of documented adverse events over that extended time frame.


Q: Does the medicine need to be taken at a specific time of day for best results?

The medicine is designated for once-daily use. To help maintain consistent drug levels, some official sources indicate that the medicine should be consumed at approximately the same time each day, such as 30 minutes after a meal.


Q: Is Omexel L.P. a medicine that must be taken continuously or only as needed?

Omexel L.P. is indicated for the chronic management of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). Regulatory documents mention that the investigation into abrupt treatment discontinuation was conducted to understand possible adverse withdrawal effects.


Q: Is Omexel L.P. used to treat conditions other than the primary approved indication?

The approved indication for Omexel L.P. is strictly the management of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) in adult males. While clinical evidence references exploratory research into other uses, such as chronic pain management, these are not listed as officially approved uses.


Q: What are the signs of a serious, rare side effect of Omexel L.P. that require immediate attention?

The official labeling documents a number of severe but rare adverse reactions. These include syncope (fainting), angioedema (swelling of the face or throat), Stevens-Johnson syndrome (a severe skin reaction), and priapism (a persistent, painful erection). These events are part of the drug's documented safety profile.


Q: How quickly should a person expect to feel the initial effects of Omexel L.P.?

Official clinical study results report a rapid initial decrease in symptom scores, such as those measured by the American Urological Association (AUA) scale. This initial change in symptoms may be reported as early as 1 week after beginning treatment.


Q: What is the typical time frame to experience the full benefit of Omexel L.P.?

Studies indicate that the full therapeutic effects, as measured by objective symptom scores, may require a period of consistent use. The full effect of the medicine is described in clinical documents as developing over a typical timeframe of up to 2 to 4 weeks of consistent use.


Q: Are there official warnings about taking Omexel L.P. with alcohol?

Yes, official sources indicate that taking the medicine with alcohol may enhance the drug's blood pressure-lowering effect. This increased effect can raise the risk of experiencing symptoms such as dizziness or light-headedness.


Q: Does Omexel L.P. interact with common over-the-counter pain relievers?

Official documents note that while some specific pain relievers are documented to affect tamsulosin levels, some common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are generally classified as having no known direct interaction.


Q: Are there specific warnings for patients with a history of heart rhythm issues?

Post-marketing safety reports have documented rare occurrences of cardiac events, including atrial fibrillation and arrhythmia, as potential adverse reactions associated with tamsulosin. This information notes that caution may be considered in patients who have a history of pre-existing heart rhythm issues.


Q: Can Omexel L.P. affect a person's ability to drive or operate machinery?

Official product information indicates that side effects like dizziness can occur with the medication. Due to this potential effect, official guidance includes warnings that patients should exercise caution regarding activities like driving or operating heavy machinery until their individual response to the medication is known.


Q: What official information is available about Omexel L.P. and fertility?

Adverse reaction reports indicate that some men may experience ejaculation problems, such as little or no semen. Furthermore, official documents mention that animal studies have demonstrated significantly reduced male fertility due to the impairment of ejaculation, though this effect was reversible.


Q: Do patients with a sulfa allergy have a higher risk of reaction to Omexel L.P.?

Official labeling states that an allergic reaction to tamsulosin in patients with a known sulfa allergy has been rarely reported. Caution is advised by the labeling, especially in individuals who report a serious or life-threatening allergy to sulfa drugs.


Q: What research themes have been explored regarding Omexel L.P.'s effect on sleep?

Official adverse reaction lists indicate that the drug can potentially affect sleep. Documented side effects include both somnolence (sleepiness) and insomnia (difficulty sleeping). These reports confirm that the drug's effect on sleep is part of its documented safety profile.


Q: Does Omexel L.P. have known interactions with common herbal or vitamin supplements?

Official sources caution that insufficient information exists to fully confirm the safety of complementary medicines and herbal remedies when taken with tamsulosin. This is primarily due to the active substance being metabolized by specific liver enzymes that can be affected by various supplements.

Advertisements

How should Omexel L.P. be stored and disposed of?

How to Store and Dispose of Omexel L.P.

The official storage requirements for Omexel L.P. (tamsulosin hydrochloride prolonged-release tablets) mandate specific environmental and packaging conditions to maintain product stability and integrity.


Storage Requirements

The medicine must be stored at a temperature below 30 C (86 F) and kept out of the sight and reach of children. To ensure protection from moisture, the tablets must remain in the original package (blister pack and outer carton) and should not be removed until immediately before use.


Disposal Instructions

Unused or expired Omexel L.P. must not be disposed of via household waste or flushed down the toilet. The product should be returned to a pharmacist or a designated collection point, following local requirements for the disposal of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Omexel L.P. found in:

A-Z Index: